BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
BeiGene, a global oncology company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024. The company, traded as BGNE on NASDAQ, 06160 on HKEX, and 688235 on SSE, will engage in a fireside chat at 10 a.m. EDT.
Investors and interested parties can access a live webcast of the event through BeiGene's investor relations websites. The webcast will be archived and available for 180 days after the event, providing extended access to the company's insights and discussions from the conference.
BeiGene, un'azienda globale nel settore oncologico, ha annunciato la sua partecipazione al 22° Annual Global Healthcare Conference di Morgan Stanley che si svolgerà il 5 settembre 2024. L'azienda, quotata come BGNE su NASDAQ, 06160 su HKEX e 688235 su SSE, parteciperà a una conversazione informale alle 10:00 EDT.
Gli investitori e gli interessati possono accedere a un webcast live dell'evento tramite i siti web delle relazioni con gli investitori di BeiGene. Il webcast sarà archiviato e disponibile per 180 giorni dopo l'evento, fornendo accesso prolungato alle intuizioni e alle discussioni dell'azienda durante la conferenza.
BeiGene, una empresa global de oncología, ha anunciado su participación en la 22ª Conferencia Anual de Atención Médica Global de Morgan Stanley el 5 de septiembre de 2024. La empresa, que cotiza como BGNE en NASDAQ, 06160 en HKEX y 688235 en SSE, participará en un chat informal a las 10 a.m. EDT.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo del evento a través de los sitios web de relaciones con inversores de BeiGene. La transmisión será archivada y estará disponible durante 180 días después del evento, proporcionando acceso ampliado a las ideas y discusiones de la empresa durante la conferencia.
BeiGene는 글로벌 항암 치료 회사로서 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스에 2024년 9월 5일 참석한다고 발표했습니다. 이 회사는 NASDAQ에서 BGNE로, HKEX에서 06160으로, SSE에서 688235로 거래되고 있으며, 동부 표준시 오후 10시에 대화식 채팅에 참여할 예정입니다.
투자자 및 관심 있는 분들은 BeiGene의 투자자 관계 웹사이트를 통해 이벤트의 실시간 웹캐스트에 접근할 수 있습니다. 웹캐스트는 이벤트 후 180일 동안 보관되어 기업의 통찰력 및 회의 내용에 대한 장기적인 접근을 제공합니다.
BeiGene, une entreprise mondiale spécialisée en oncologie, a annoncé sa participation à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley le 5 septembre 2024. L'entreprise, cotée sous le symbole BGNE sur NASDAQ, 06160 sur HKEX, et 688235 sur SSE, participera à une discussion informelle à 10 h EDT.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de l'événement via les sites web de relations investisseurs de BeiGene. Le webinaire sera archivés et disponible pendant 180 jours après l'événement, offrant un accès prolongé aux idées et aux discussions de l'entreprise lors de la conférence.
BeiGene, ein globales Onkologieunternehmen, hat seine Teilnahme an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley am 5. September 2024 angekündigt. Das Unternehmen, das an der NASDAQ als BGNE, an der HKEX als 06160 und an der SSE als 688235 notiert ist, wird an einem informellen Gespräch um 10 Uhr EDT teilnehmen.
Investoren und interessierte Parteien können über die Investor-Relations-Websites von BeiGene auf ein Live-Webcast der Veranstaltung zugreifen. Das Webcast wird archiviert und ist 180 Tage nach der Veranstaltung verfügbar, sodass längerfristiger Zugang zu den Erkenntnissen und Diskussionen des Unternehmens während der Konferenz gewährt wird.
- None.
- None.
The live webcast of this event can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 180 days following the event.
About BeiGene
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter) and Facebook and Instagram.
Forward-Looking Statements
This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's plans, commitments, aspirations and goals related to BeiGene’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828469416/en/
Investors:
Liza Heapes
+1 857-302-5663
ir@beigene.com
Media:
Kyle Blankenship
+1 667-351-5176
media@beigene.com
Source: BeiGene, Ltd.
FAQ
When is BeiGene (BGNE) participating in the Morgan Stanley Global Healthcare Conference?
What time is BeiGene's fireside chat at the Morgan Stanley conference?
How can investors access BeiGene's presentation at the Morgan Stanley conference?
How long will the replay of BeiGene's Morgan Stanley conference presentation be available?
What stock exchanges is BeiGene (BGNE) listed on?
